1. A pharmaceutical combination for use in treating a patient with type 2 diabetes, said combination comprising (a) des Proeksendin-4 (1-39) -Lys-NHili / and a pharmaceutically acceptable salt thereof, and (b) metformin or / and a pharmaceutically acceptable salt thereof, wherein the compound (a) is administered once a day in the range of from 4 hours to 15 minutes before taking the morning meal, where the patient to be treated has a concentration of glucose in plasma 2 hours after eating at least 14 mM /l.2. Pharmaceutical combination according to claim 1, wherein the individual is to be treated has a glucose fluctuations in the blood level of at least 2 mmol / l, at least 3 mmol / l, at least 4 mmol / l or at least 5 mmol / l where oscillation glucose represents the difference between the concentration of glucose in plasma 2 hours after ingestion, and the glucose concentration in the plasma at 30 minutes before the provocative test with the reception pischi.3. Pharmaceutical combination according to claim 1 or 2, wherein the individual is to be treated has ozhirenie.4. Pharmaceutical combination according to claim 1 or 2, wherein the individual to be treated, has a body mass index of at least 30 kg / M.5. Pharmaceutical combination according to claim 1 or 2, wherein the individual to be treated is adult individuumom.6. Pharmaceutical combination according to claim 1 or 2, wherein diabetes type 2 is not sufficiently controlled otdelno.7 metformin treatment. Pharmaceutical combination according to claim 1 or 2, where a subject to be treated, type 2 diabetes mellitus was diagnosed at least 1 year or at least 2 years before the terapii.8. Pharmaceutical combination according to claim 1 or 2, wherein the individual is to be treated has a value of about 7 to HbAot n1. Фармацевтическая комбинация для применения в лечении пациента с диабетом 2 типа, причем указанная комбинация содержит(a) дез-Pro36эксендин-4(1-39)-Lys6-NH2 или/и его фармацевтически приемлемую соль, и(b) м
